Trial reportmSphere2020
Distinct Fecal and Plasma Metabolites in Children with Autism Spectrum Disorders and Their Modulation after Microbiota Transfer Therapy.
Trial report in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 86 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treating Gastrointestinal Problems in Children With Autism Using Beneficial Bacteria Treatment (BBT)
Gut Mobilization With Oral Administration of Polyethylene Glycol (PEG) at the Dose of 6.9 g/d Once a Day for 6 Months in Chronically Constipated Autistic Children.
Who cites it
86 citing papers in PubMed, 3 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- Biomarkers and pathways in autism spectrum disorder: An individual meta-analysis based on proteomic and metabolomic data.European archives of psychiatry and clinical neuroscience · 2025Pooled it
- Recognition of the microbial metaboliteFrontiers in molecular neuroscience · 2025Pooled it
- Pooled it
- Trial
- Anti-Inflammatory Diet and Probiotic Supplementation as Strategies to Modulate Immune Dysregulation in Autism Spectrum Disorder.Nutrients · 2025Trial
- Probiotic Therapy of Gastrointestinal Symptoms During COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled, Remote Study.Nutrients · 2024Trial
- Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial.Nature medicine · 2022Trial
- Elevated microbially-derived metabolites in autism: a possible diagnostic screening test for a distinct ASD phenotype.Molecular psychiatry · 2026Article
- Gut microbiota-derived 5-HTP penetrates the host blood-brain barrier and ameliorates autism symptoms.Acta pharmaceutica Sinica. B · 2026Article
- Microbiota-gut-brain axis in autism spectrum disorder: integrating brain structure, function, and transcriptomics.Translational psychiatry · 2026Review
- Gut-Derived Metabolic Imbalance in Autism Spectrum Disorder: Toward the Concept of a Metabolic Subtype.Nutrients · 2026Review
- Article
- Microbial Metabolite 4EPS Inhibits AT1R to Reduce Blood Pressure and Aortic Aneurysm Outcome.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Integrative multi-omics reveals microbial genomic variants driving altered host-microbe interactions in autism spectrum disorder.Cell reports. Medicine · 2026Article
- Targeted stool metabolomics suggests exploratory catecholamine- and tryptophan-linked metabolic features in autism spectrum disorder.Frontiers in neuroscience · 2026Article
- Gut microbiota dysbiosis in autism spectrum disorder: 10 years of progress on compositional alterations, metabolic/immune mechanisms, and therapeutic strategies.Frontiers in neuroscience · 2026Review
- Research progress on the microbiota-gut-brain axis in autism spectrum disorder: a narrative review.Frontiers in microbiology · 2026Review
- Oral microbiome dysbiosis in autism spectrum disorder: the oral-gut-brain axis and future perspectives: a narrative review.Frontiers in microbiology · 2026Review
- Faecal inflammatory protein markers in children with autism spectrum disorder are comparable to their healthy siblings.Frontiers in psychiatry · 2026Article
- HUBMet: an integrative database and analytical platform for human blood metabolites and metabolite-protein associations.Genome biology · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence has strengthened a link between dysbiotic gut microbiota and autism. Fecal microbiota transplant (FMT) is a promising therapy to repair dysbiotic gut microbiota. We previously performed intensive FMT called microbiota transfer therapy (MTT) for children with autism spectrum disorders (ASD) and observed a substantial improvement of gastrointestinal and behavioral symptoms. We also reported modulation of the gut microbiome toward a healthy one. In this study, we report comprehensive metabolite profiles from plasma and fecal samples of the children who participated in the MTT trial. With 619 plasma metabolites detected, we found that the autism group had distinctive metabolic profiles at baseline. Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the ASD group at baseline, while caprylate and heptanoate were significantly higher in the ASD group. MTT drove global shifts in plasma profiles across various metabolic features, including nicotinate/nicotinamide and purine metabolism. In contrast, for 669 fecal metabolites detected, when correcting for multiple hypotheses, no metabolite was significantly different at baseline. Although not statistically significant,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.